A Breakthrough for Organ Support
MitoQ’s patented technology delivers powerful antioxidant support to mitochondria, the power source of your cells, restoring their vitality so they can fight the symptoms of aging and support organ health.
Why MITOQ Supplements?
MitoQ is a mitochondria-targeted antioxidant designed to accumulate within mitochondria in vivo in order to protect against oxidative damage. It is the ﬁrst molecule speciﬁcally designed to decrease mitochondrial oxidative damage to have undergone clinical trials in humans.
Mitochondria are an essential organelle within most cells that use oxygen to break down carbohydrates and fat to release energy in a form the cell can use. In doing this mitochondria release disruptive free radicals that contribute to oxidative damage in a wide range of diseases and pathologies. The active antioxidant component of MitoQ is ubiquinone, which is identical to the active antioxidant in Coenzyme Q10. The lipophilic cation enables MitoQ to be accumulated selectively and extensively by mitochondria, in contrast to other antioxidants which distribute evenly throughout the cell. It is this approximately thousand-fold greater concentration of MitoQ within mitochondria that makes it more effective at preventing mitochondrial oxidative damage when compared to untargeted antioxidants such as Coenzyme Q10.
MitoQ was designed in the late 1990s by Michael P. Murphy and Robin A. J. Smith. At the time, both were at the University of Otago, Dunedin, New Zealand where Murphy was a mitochondrial biochemist in the Department of Biochemistry and Smith was an organic chemist at the Department of Chemistry. Since then over 200 publications on MitoQ have been recorded.
About Human Studies:
The protection against mitochondrial oxidative damage by MitoQ in disease models led to MitoQ being translated to human clinical trials. The concept of mitochondria-targeted antioxidants based on lipophilic cations invented by Murphy and Smith was patented by the University of Otago, New Zealand (e.g. US 6331532, NZ 505302, AU 763179). These patents were then acquired by Antipodean Pharmaceuticals Inc, an Auckland, NZ based company which developed MitoQ as an oral agent and established a suite of further patents in this area.
To do this, Antipodean Pharmaceuticals carried out toxicity studies leading on to a successful Phase I assessment of oral MitoQ tablets in healthy volunteers and then to two Phase II clinical trials. One on the Phase II clinical trials was on Parkinson’s disease where patients were given an oral MitoQ dose of 40 or 80 mg per day for a year and compared with placebo. This trial was registered on clinicaltrials.gov as NCT00329056.
In the other trial patients with hepatitis C virus who were not responding to antiviral treatments were assessed for prevention of liver inﬂammation. This trial was registered on clinicaltrials.gov as NCT00433108. The Parkinson’s Disease trial did not show a beneﬁt of MitoQ, probably because the irreversible neuronal damage was too great by the time the patients were diagnosed, however this study did provide a year’s safety data.
The trial in hepatitis C virus patients did show liver protection. These two trials showed that it was safe to target mitochondria in humans long term and other trials for MitoQ are now planned.